or Try an Advanced Search...

    Technical Analysis for ZURA - Zura Bio Limited

    Grade Last Price % Change Price Change
    F 2.90 -7.94% -0.25
    ZURA closed down 7.94 percent on Wednesday, November 20, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ZURA trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Spinning Top Other -7.94%
    Lower Bollinger Band Walk Weakness -7.94%
    Outside Day Range Expansion -7.94%
    Wide Bands Range Expansion -7.94%
    Older End-of-Day Signals for ZURA ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR about 16 hours ago
    Down 10% about 16 hours ago
    60 Minute Opening Range Breakdown about 18 hours ago
    Down 5% about 18 hours ago
    Down 3% about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ZURA Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Zura is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Immunology Diabetes Monoclonal Antibody Antibody

    Is ZURA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
    Nov 7 Zura Bio GAAP EPS of -$0.26 misses by $0.13
    Nov 7 Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
    Oct 30 Zura Bio to Participate in Two Upcoming Investor Conferences in November
    Oct 17 Bullish Zura Bio Insiders Loaded Up On US$1.01m Of Stock
    Sep 20 Institutions profited after Zura Bio Limited's (NASDAQ:ZURA) market cap rose US$45m last week but private equity firms profited the most
    Sep 3 Zura Bio files for $300M mixed securities shelf
    Sep 3 Zura Bio to Present at Three Upcoming Investor Conferences in September
    Aug 15 We're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Rate
    Aug 14 Zura Bio GAAP EPS of -$0.17
    See more ZURA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.35
    52 Week Low 2.0
    Average Volume 482,781
    200-Day Moving Average 3.87
    50-Day Moving Average 4.18
    20-Day Moving Average 4.17
    10-Day Moving Average 3.87
    Average True Range 0.35
    RSI (14) 27.54
    ADX 21.19
    +DI 16.33
    -DI 37.02
    Chandelier Exit (Long, 3 ATRs) 3.91
    Chandelier Exit (Short, 3 ATRs) 3.83
    Upper Bollinger Bands 5.33
    Lower Bollinger Band 3.00
    Percent B (%b) -0.04
    BandWidth 56.08
    MACD Line -0.29
    MACD Signal Line -0.10
    MACD Histogram -0.1896
    Fundamentals Value
    Market Cap 124.97 Million
    Num Shares 43.1 Million
    EPS 0.15
    Price-to-Earnings (P/E) Ratio 19.33
    Price-to-Sales 0.00
    Price-to-Book 2.67
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.68
    Resistance 3 (R3) 3.72 3.51 3.55
    Resistance 2 (R2) 3.51 3.31 3.49 3.50
    Resistance 1 (R1) 3.21 3.19 3.10 3.16 3.46
    Pivot Point 2.99 2.99 2.94 2.97 2.99
    Support 1 (S1) 2.69 2.79 2.58 2.64 2.34
    Support 2 (S2) 2.47 2.67 2.45 2.30
    Support 3 (S3) 2.17 2.47 2.25
    Support 4 (S4) 2.12